Surgical management of high-grade gliomas

References

• Castro MG, Cowen R, Williamson IK et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol. Ther. 98, 71–108 (2003).
   PubMed Web of Science ®Google Scholar
• Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J. Neurooncol. 42, 227–231, (1999).
   PubMed Web of Science ®Google Scholar
• Sawaya R. Extent of resection in malignant gliomas: a critical summary. J. Neurooncol. 42, 303–305 (1999).
   PubMed Web of Science ®Google Scholar
• Simpson JR, Horton J, Scott C et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 26, 239–244 (1999).
   Google Scholar
• Metcalfe SE, Grant R. Biopsy versus resection for malignant glioma. Cochrane Database Syst. Rev. 3, CD002034 (2001).
   Google Scholar
• Quigley MR, Flores N, Maroon JC, Sargent B, Lang S, Elrifai A. Value of surgical intervention in the treatment of glioma. Stereotact. Funct. Neurosurg. 65, 171–175 (1995).
   Google Scholar
• Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg. Neurol. 52, 371–379 (1999).
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 95, 190–198 (2001).
   PubMed Web of Science ®Google Scholar
• Polin RS, Marko NF, Ammerman MD et al. Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres. J. Neurosurg. 102, 276–283 (2005).
   PubMed Web of Science ®Google Scholar
• Quigley MR, Maroon JC. The relationship between survival and the extent of the resection with supratentorial malignant gliomas. Neurosurgery 29, 385–388 (1991).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Vastola F, Basso U et al. A prospective study on glioblastoma in the elderly. Cancer 97, 657–662 (2003).
   PubMed Web of Science ®Google Scholar
• Whittle IR, Basu N, Grant R, Walker M, Gregor A. Management of patients aged >60 years with malignant glioma: good clinical status and radiotherapy determine outcome. Br. J. Neurosurg. 16, 343–347 (2002).
   PubMed Web of Science ®Google Scholar
• Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J. Cancer Res. Clin. Oncol. 129, 477–484 (2003).
   PubMed Web of Science ®Google Scholar
• Young B, Oldfield EH, Markesbery WR et al. Reoperation for glioblastoma. J. Neurosurg. 55, 917–921 (1981).
   PubMed Web of Science ®Google Scholar
• Vick NA, Ciric IS, Eller TW, Cozzens JW, Walsh A. Reoperation for malignant astrocytoma. Neurology 39, 430–432 (1989).
   Google Scholar
• Daneyemez M, Gezen F, Canakci Z, Kahraman S. Radical surgery and reoperation in supratentorial malignant glial tumors. Minim. Invasive Neurosurg. 41, 209–213 (1998).
   PubMedGoogle Scholar
• Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21, 607–614 (1987).
   PubMed Web of Science ®Google Scholar
• Dirks P, Bernstein M, Muller PJ, Tucker WS. The value of reoperation for recurrent glioblastoma. Can. J. Surg. 36, 271–275 (1993).
   PubMed Web of Science ®Google Scholar
• Croenen VA, Krings T, Mayfrank L et al. Three-dimensional visualization of the pyramidal tract in a neuronavigation system during brain tumor surgery: first experiences and technical note. Neurosurgery 49, 86–92 (2001).
   Google Scholar
• Nabavi A, Black PM, Gering DT et al. Serial intraoperative magnetic resonance imaging of brain shift. Neurosurgery 48, 787–797 (2001).
   PubMed Web of Science ®Google Scholar
• Nimsky C, Ganslandt O, Hastreiter P et al. Intraoperative compensation for brain shift. Surg. Neurol. 56, 357–364 (2001).
   PubMed Web of Science ®Google Scholar
• Unsgaard G, Ommedal S, Muller T et al. Neuronavigation by intraoperative three-dimensional ultrasound: initial experience during brain tumor resection. Neurosurgery 50, 804–812 (2002).
   PubMed Web of Science ®Google Scholar
• Meyer FB, Bates LM, Goerss SJ et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo Clin. Proc. 76, 677–687 (2001).
   PubMed Web of Science ®Google Scholar
• Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor affecting outcome. J. Neurosurg. 95, 735–747 (2001).
   PubMed Web of Science ®Google Scholar
• Peraud A, Meshede M, Eisner W et al. Surgical resection of grade II astrocytomas in the superior frontal gyrus. Neurosurgery 50, 966–977 (2002).
   PubMed Web of Science ®Google Scholar
• Walker MD et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A co-operative clinical trial. J. Neurosurg. 49, 333–343 (1978).
   PubMed Web of Science ®Google Scholar
• Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl Cancer Inst. 85, 704–710 (1993).
   PubMed Web of Science ®Google Scholar
• Keles GE, Lamborn KR, Chang SM et al. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J. Neurosurg. 100, 41–46 (2004).
   PubMed Web of Science ®Google Scholar
• Scharfen CO, Sneed PK, Wara WM et al. High activity iodine-125 interstitial implant for gliomas. Int. J. Radiat. Oncol. Biol. Phys. 24, 583–591 (1992).
   PubMed Web of Science ®Google Scholar
• Nehls DG, Shetter AG, Rossman KJ. Interstitial irradiation of malignant tumors. BNI Q. 1, 34 (1985).
   Google Scholar
• Patel S, Breneman JC, Warnick RE et al. Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurosurgery 46, 1123–1128 (2000).
   Google Scholar
• Fernandez PM, Zamorano L, Yakar D et al. Permanent iodine-125 implants in the up-front treatment of malignant gliomas. Neurosurgery 36, 467–473 (1995).
   Google Scholar
• Selker RG, Shapiro WR, Burger P et al. The Brain Tumor Co-operative Group NIH Trial 87–01: a randomised comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51, 343–355 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson CB, Larson DA, Gutin PH. Radiosurgery: a new application? J. Clin. Oncol. 10, 1373–1374 (1992).
   Google Scholar
• Tatter SB, Shaw EG, Rosenblum ML et al. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J. Neurosurg. 99, 297–303 (2003).
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345, 1008–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5, 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Archer GE, McLendon RE et al. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin. Cancer Res. 6, 4148–4153 (2000).
   PubMed Web of Science ®Google Scholar
• The PRECISE Trial: Phase III randomized evaluation of convection enhanced delivery IL13-PE38QQR compared to Gliadel wafer with survival end point in glioblastoma multiforme patients at first relapse. NeoPharm, Inc., Lake Forest IL, USA.
   Google Scholar
• KSB311R/C11/001: A Phase III multicenter study of intratumoral/interstitial therapy with TransMID compared to best standard of care in patients with progressive and/or recurrent, non-resectable glioblastoma multiforme. Xenova Biomedix Ltd, Berkshire, UK.
   Google Scholar